ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Couple claim eye antibiotic cured dog of mysterious illness sweeping America

A California couple are claiming their canine recovered from a potentially deadly disease after being treated with a lifesaving antibiotic.

A cure to a mysterious and potentially deadly respiratory condition that has been spreading in dogs throughout the country may have been found with a California couple who claim their canine is on the road to recovery after he received a lifesaving antibiotic. 

John and Becky Oliver say their dog was on death’s door with the disease – known as Canine Infectious Respiratory Disease Complex (CIRDC), which starts off as a cough and can develop into potentially deadly pneumonia-like symptoms. The illness had been thought to be resistant to traditional antibiotic treatments.

The couple say their dog, an award-winning golden retriever called Ike, contracted CIRDC while competing in dog shows in September and was immediately quarantined behind glass when he was brought to a veterinarian. Photos posted online show the dog lying down with tubes inserted into his snout and a cone around his head.

'KELCE' BECOMES A TOP TRENDING DOG NAME IN AMERICA, PET COMPANY'S DATA SHOWS

The veterinarians were stumped as to what was wrong with the Olivers' prized pet, who has ranked among the top five golden retrievers in U.S. shows.

"They had given up, and (Ike) was starting to give up," Becky Oliver told ABC.

"He couldn't go in the room with them, no other dogs were in there with him, so that's how contagious this is," John Oliver added. 

After multiple tests, vets determined Ike was infected with CIRDC.

The Olivers took to Facebook to tell their friends about Ike’s worsening condition, and they were then contacted by a stranger who advised them to try chloramphenicol – an antibiotic used as an eye ointment to treat human conjunctivitis, also known as pink eye.

After giving Ike the drug, his condition eventually improved and the Olivers were able to take him home from the vet.

"The vet hospital called to say Ike was off of oxygen support and was ready to come home! Hearing he could come home was like a dream," Becky wrote on Facebook, according to the Daily Mail.

'MIRACLE DOG' RECOVERS AFTER SURVIVING 10 WEEKS IN COLORADO MOUNTAINS FOLLOWING OWNER'S DEATH

"Ike has been doing pretty good since he has been home. He is, however very, very thin and weak. His appetite is very good and he has been doing his normal things with lots of rest in between."

She warned that chloramphenicol is a powerful drug, but it seemed to have worked.

Chloramphenicol is "a very, very strong last-resort antibiotic, but it's what saved him. Otherwise, he would not be here," she wrote. 

The news that the drug worked effectively in Ike will provide hope for other dog owners whose pets may have come down with the mysterious illness.

Cases of the condition in dogs have appeared in Oregon, Indiana, Illinois, Washington, Idaho, California, Nevada and throughout the Northeast as veterinarians scramble to determine how to treat it.

Although the American Veterinary Medical Association told "Today" they are monitoring cases of the condition in other states, it is unclear how many pets have suffered nationwide. 

Since mid-August, the Oregon Department of Agriculture has received over 200 reports of the unidentified condition, per a Nov. 9 press release. A research lab in New Hampshire says it has been studying the illness since 2022.

Dr. Lindsay Ganzer, a veterinarian at North Springs Veterinary Referral Center in Colorado Springs, told "Today" that dogs are most likely to contract the condition by being in close contact with numerous other dogs at day care, groomers, boarding kennels and dog parks.

Fox News Digital's Christina Coulter contributed to this report.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.